Novo Nordisk A/S (NOVOB), the world’s biggest insulin maker, plans to hire about 1,000 people in the next two years to expand treatment for diabetes in emerging markets such as Vietnam. The Danish company wants to grow in Colombia, Egypt, Ukraine, Malaysia and Indonesia, as well as Vietnam in the years to come, Jesper Hoiland, who heads Novo’s international operations, said in an interview. Novo is adding headcount “rapidly” in these countries, Hoiland said yesterday in Berlin, where he attended the European Association for the Study of Diabetes conference. “Vietnam is going to be a new mini-China.”
